

Adaptimmune Therapeutics PLC  
 Form 3  
 January 04, 2016

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Binder-Scholl Gwendolyn Knowlton		(Month/Day/Year) 01/01/2016	Adaptimmune Therapeutics PLC [ADAP]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
1903 CARPENTER STREET			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
PHILADELPHIA,Â PAÂ 19146			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below) (specify below) EVP, Adaptimmune LLC	
			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable      Expiration Date	Title      Amount or Number of Shares			

(Instr. 5)

Option to purchase Ordinary Shares	Â (1)	03/01/2021	Ordinary Shares	300,000	\$ 0.1736 (5)	D	Â
Option to purchase Ordinary Shares	Â (2)	01/01/2023	Ordinary Shares	200,000	\$ 0.1671 (6)	D	Â
Option to purchase Ordinary Shares	Â (3)	04/15/2024	Ordinary Shares	500,000	\$ 0.1671 (7)	D	Â
Option to purchase Ordinary Shares	Â (4)	12/19/2024	Ordinary Shares	1,000,000	\$ 0.5308 (8)	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Binder-Scholl Gwendolyn Knowlton 1903 CARPENTER STREET PHILADELPHIA, PA 19146	Â	Â	Â EVP, Adaptimmune LLC	Â

## Signatures

/s/ Gwendolyn Knowlton Binder-Scholl Name: Gwendolyn Knowlton Binder-Scholl

01/04/2016

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Currently exercisable as to 300,000 Ordinary Shares.

(2) Currently exercisable as to 150,000 Ordinary Shares and will be exercisable as to 50,000 Ordinary Shares on January 1, 2017.

(3) Exercisable as to 125,000 Ordinary Shares on April 15, 2015 and exercisable as to the remainder ratably in annual installments on the fifteenth of April from April 15, 2016 through April 15, 2018.

(4) Exercisable as to 250,000 Ordinary Shares on December 19, 2015 and will be exercisable as to the remainder in monthly installments of 20,800 Ordinary Shares on the nineteenth of each month from January 19, 2016 through November 19, 2018, and in one installment of 22,000 Ordinary Shares on December 19, 2018.

(5) The exercise price was converted from GBP0.1163 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(6) The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(7) The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

(8) The exercise price was converted from GBP0.3557 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.